BUKWANG PHARM is a pharmaceutical company established in 1960 that develops, manufactures, and sells prescription drugs, over-the-counter medicines, and health functional foods. Its product portfolio includes Dexid, Feroval, Regaron, Chioctacid, and Latuda, with a focus on central nervous system (CNS) disorders such as schizophrenia, bipolar disorder, and Parkinson's disease. The company operates through subsidiaries including Contera Pharma, ProteKt Therapeutics, and JaguAHR Therapeutics, which focus on R&D for RNA therapeutics and rare diseases. BUKWANG PHARM engages in open innovation partnerships, including a strategic research collaboration with Lundbeck for RNA drug discovery and a license-in agreement with Sumitomo Pharma for Latuda. It also acquired Hanuk Union Pharma to strengthen its manufacturing capabilities. The company serves domestic hospitals, pharmacies, and wholesalers, and exports products to markets in Southeast Asia, including Thailand.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage bukwang.co.kr
Sector Healthcare IR page —
Tags
central nervous system, rna therapeutics, parkinson's disease, schizophrenia, bipolar disorder, rare diseases, open innovation, health functional foods, Dexid, Feroval, Regaron, Chioctacid, Latuda, Clevudine, Levovir, Regadex, Ariplus, Circaredep, Erojet, Contera Pharma, ProteKt Therapeutics, JaguAHR Therapeutics, Hanuk Union Pharma, ImmPACT Bio USA Inc., Lundbeck, Sumitomo Pharma, Viatris, Cooper Consumer Health, Melior, Biodexa, Pacific Healthcare, AttackPoint, OligoDisc, SpliceMatrix, CP-012, JM-010, MLR-1023, CP-102
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 4.3%
ROI 3.7%
ROIC 4.2%
Profit margin 6.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 200.714B 160.087B 125.928B 190.909B 182.491B 169.66B 168.194B 194.224B 150.743B 138.618B 142.132B 141.687B 130.795B
Net profit 12.558B -2.641B -31.33B -2.475B -916.622M -7.203B -7.412B 145.67B 11.091B 15.807B 25.139B 23.616B 19.532B
Free cash flow 14.206B 32.424B -12.196B 13.224B 25.758B -1.194B -26.945B 3.109B 4.077B -11.475B 5.719B 24.897B 32.771B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 49.5B 59.9B 86.3B 103B 104B 90.4B 88B 35.7B 23.6B —
↳ YoY growth +11.8% +21.1% +43.9% +19.2% +0.8% -12.8% -2.7% -59.4% -34.1%
↳ 5y CAGR +18.3% +23.3% +18.6% +12.8% +8.0% -16.2% -25.5%
Borrowings, current (KRW) — — 0.00 0.00 20B — — — 0.00 —
Borrowings, non-current (KRW) — — — — — 0.00 0.00 78.5B 79B —
Lease liabilities (KRW) — 0.00 0.00 434M 408M 1.56B 931M 862M 400M 809M
Cash and deposits (KRW) 41.1B 24.2B 100B 37.6B 79.3B 82.8B 85.5B 151B 90.1B 96.2B
Intangible assets (KRW) 12B 13.3B 8.97B 10.4B 7B 6.98B 6.99B 10.1B 6.28B 5.05B
Right-of-use assets (KRW) — — 0.00 2.3B 1.68B 1.6B 2.05B 1.81B 1.06B 1.26B
Net debt (borrowings + leases - cash) (KRW) — — -100B -37.6B -58.9B -81.2B -84.6B -71.8B -10.7B —
Cash flow detail
Operating cash flow (KRW) -7.76B 8.56B 6.82B -23.4B 723M 26.5B 16.5B -9.36B 34.4B 21.5B
Purchases of property, plant and equipment (KRW) -3.71B -4.49B -3.71B -3.54B -1.92B -785M -3.24B -2.83B -1.94B -7.26B
Purchases of intangible assets (KRW) -2.22B -2.04B -18.5M -1.37B -36.9M -4.47M -692M 0.00 -674M -3.94B
Change in receivables (cash effect) (KRW) -5.61B -10.5B -25.2B -19.1B 6.66B 11.6B -424M 57.1B 12.9B —
Change in inventories (cash effect) (KRW) -1.04B -261M 7.9B -9.92B -7.81B 12.2B 208M -18.4B 14.3B —
Change in payables (cash effect) (KRW) -135M 1.41B -2.73B 7.06B -1.1B -2.73B 9.15B -14.2B 2.43B —
Dividends paid (cash effect) (KRW) -22.8B -17.9B -8.61B -9.77B -12.2B -6.23B -6.85B 0.00 0.00 -4.93B
Share buybacks (cash effect) (KRW) -87.1M -80.3M -110M -50.2B -25.1B -516M 0.00 0.00 — —
Interest paid (cash effect) (KRW) -1.52M 0.00 0.00 — — -291M -147M -1.14B -4.03B -2.98B
Income taxes paid (cash effect) (KRW) -7.88B -4.22B -7.38B -29.6B -9.09B -8.93B -4.12B -900M -1.59B 8.44B
Share-based compensation (KRW) 0.00 0.00 323M 348M 3.23B 3.41M 44.3M 147M -3.53M —
Operating cash flow before change in receivables (KRW) -2.15B 19.1B 32B -4.27B -5.94B 15B 16.9B -66.5B 21.4B —
Free cash flow (OCF - PPE - intangibles) (KRW) -13.7B 2.03B 3.09B -28.3B -1.23B 25.8B 12.5B -12.2B 31.7B 10.3B
Income detail
Total comprehensive income (KRW) 11.7B 14.7B 171B -27.7B -13.4B 15.6B 133M -37.8B 9.62B 13.6B
Comprehensive income to owners (KRW) 11.7B 14.7B 171B -27.6B -10.4B 17.6B 1.76B -34.9B 10.3B 13.7B
Provision for credit losses (KRW) 217M 98M 673M 1.13B 1.26B 1.69B 2.9B -4.9B -555M —
Credit cost ratio (credit losses / average receivables) (%) 0.5% 0.2% 0.9% 1.2% 1.2% 1.7% 3.3% 7.9% 1.9% —
Reported Aug 14, 2019 Mar 27, 2020 Mar 27, 2020 Mar 24, 2021 Mar 24, 2021 Mar 22, 2024 Mar 22, 2024 Mar 22, 2024 Nov 14, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

기업설명회(IR)개최(안내공시) Bull 0 Bear 0 Routine
기업설명회(IR)개최(안내공시) Bull 0 Bear 0 Routine

Prompts

BUKWANG PHARM (ticker 003000), listed in South Korea.

ETFs Holding BUKWANG PHARM

ETF Weight in ETF Shares Market value As of
DEXC 0.01% 4,845 $ 14.384K Nov 12, 2026
DFSE 0.00% 8,361 $ 24.823K Nov 12, 2026
DFAE 0.00% 78,386 $ 232.722K Nov 12, 2026
DFEM 0.00% 65,146 $ 193.413K Nov 12, 2026
DFAX 0.00% 48,796 $ 144.871K Nov 12, 2026
DFEV 0.00% 7,051 $ 20.934K Nov 12, 2026
AVEM 0.00% 4,982 $ 14.371K Nov 16, 2026